HomeNewsBusinessMarketsWe estimate a 10% YoY contraction in Nifty EPS in FY21: R Venkataraman

We estimate a 10% YoY contraction in Nifty EPS in FY21: R Venkataraman

Expensive valuations (due to recent rally and depressed earnings estimate) and an uncertain recovery path (of the economy) are likely to weigh on equity markets.

July 08, 2020 / 12:09 IST
Story continues below Advertisement

A year-on-year contraction of around 10 percent is expected in Nifty EPS in FY21. In absolute terms, FY21 Nifty EPS is expected to be only slightly better than FY17/18 EPS, R Venkataraman, MD, IIFL Securities Ltd, says in an interview to Moneycontrol’s Kshitij Anand. Edited excerpts:

Q)  What according to you will weigh on Indian markets?

Story continues below Advertisement

A) We do not think that the investors are worried due to the International Monetary Fund (IMF) forecasts. The consensus forecast of GDP already points to 5 percent YoY contraction in FY21 and hence IMF outlook shouldn’t have been a negative surprise.

That said, expensive valuations (due to recent rally and depressed earnings estimate) and an uncertain recovery path (of the economy) is likely to weigh on equity markets.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show

Q) What is the one word you will use to describe the first six months of 2020 and why?
A) The one word that best describes the last six months would be ‘unprecedented’, in our view. The pandemic has led to a collapse of economies across the world.